Markus Warmuth - 01 Mar 2022 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
President & CEO, Director
Signature
/s/ Ajim Tamboli, Attorney-in-Fact
Issuer symbol
GLUE
Transactions as of
01 Mar 2022
Net transactions value
$0
Form type
4
Filing time
02 Mar 2022, 17:26:59 UTC
Previous filing
23 Jun 2021
Next filing
04 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GLUE Stock Option (Right to Buy) Award $0 +315,600 $0.000000 315,600 01 Mar 2022 Common Stock 315,600 $13.41 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter.